Advertise on podcast: Audio Journal of Oncology Podcast

Description

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoken comments on the clinical implications of cancer developments in the real-world context, as practiced by cancer doctors and clinicians around the globe. The AJO Podcast originates from the Audio Journal of Oncology staffed by ex-BBC professional journalists, and mentored by world-leading cancer practitioners from bodies including the American Society of Clinical Oncology, Cancer Research UK, Istituto Nazionale dei Tumori, and Action Radiotherapy. Each podcast is produced to the highest standards of audio recording and journalism and is subject to editorial appraisal to maintain that content, balance and clinical relevance of news and comment are delivered in a manner that's easy and enjoyable for listening while travelling, taking exercise, working or just relaxing. Please contact Audio Medica with your comments and make your contribution to supporting a vibrant community of clinical cancer communicators!

Unlock Audio Journal of Oncology Podcast podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Audio Journal of Oncology Podcast podcast

David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial

2026/10/15

CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA

Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy

2026/10/12

GLASGOW, Scotland—Patients who achieved sustained measurable residual disease negativity for more than 24 months had significantly improved survival outcomes and could be categorized as cured. This isthe implication of findings from a retrospective analysis looking at predicting cure in myeloma reported at the International Myeloma Society 2026 Annual Meeting. Sarah Maxwell heard the details from study author Zachary Avigan MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Icahn School of Medicine in Mount Sinai Hospital, New York City, USA.

Thomas E. Stinchcombe MD; CSCO 2026: The Journal of Clinical Oncology’s Mission and Vision Going Forwards: New Editor's Global Perspective

2026/10/06

JINAN, China—January 2027 sees the appointment of the new Editor-in-Chief of the Journal of Clinical Oncology who tells us (during his visit to China) he is committed to continue the policy of global co-operation in clinical cancer research publishing. He is: Thomas Eldridge Stinchcombe MD, FASCO, Medical Oncologist and Member of the Thoracic Oncology Program at Duke Cancer Institute in Durham, North Carolina, in the USA. At the 2026 Annual Meeting of the Chinese Society of Clinical Oncology he talked about his plans with our reporter, Peter Goodwin.

Fang Wu MD PhD; CSCO 2026: Could Emotional Distress Medicines Prolong Survival in Patients with Small Cell Lung Cancer?

2026/10/01

JINAN, China—Provocative evidence is emerging that emotional distress can adversely affect outcomes among patients with lung cancer. Data from a study of the role of hormones in affecting lung cancer outcomes were reported at the 2026 Annual Meeting of the Chinese Society of Clinical Oncology in an oral communication entitled: Clinical Impact of Baseline Hormones on Outcomes of First Line Immunotherapy in Extensive Stage Small-Cell Lung Cancer. Peter Goodwin discussed the findings with first author Fang Wu MD PhD, Deputy Director, Chief Physician, Professor and Doctoral Supervisor in the Department of Oncology at the Second Xiangya Hospital Cancer Center in Central South University, Changsha, China.

Luciano J. Costa MD PhD; IMS 2026: Teclistamab plus Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma brings “Dramatic Reduction” of Progression Risk, Without Increased Risk of Death: MajesTEC-3 Phase Three Study Findings

2026/09/30

GLASGOW, Scotland—A combination of the bi-specific T-cell engager antibody teclistamab (that targets both B-cell maturation antigen and CD-3) paired with the anti-CD-38 monoclonal antibody daratumumab markedly extended relapse-free survival, and improved overall survival among patients with relapsed or refractory multiple myeloma in comparison with standard of care triplet therapy. This was in the international multi-center phase three MajesTEC-3 study reported at the 2026 Annual Meeting of the International Myeloma Society. Sarah Maxwell caught up with lead author Luciano Costa MD PhD, Professor of Medicine and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama, in Birmingham, USA.

Feng Wang PhD MD; CSCO 2026: Progress and Prospects of New Drug Research for Colorectal Cancer: The View from China

2026/09/29

JINAN, China—The 2026 Annual Meeting of the Chinese Society of Clinical Oncology, with more than 40 000 cancer clinicians attending, heard evidence from clinical trial findings and new science bringing great hope for the treatment of colorectal cancer. The era of targeted precision medicine for colorectal cancer had truly arrived, delegates heard, with a long list of potential targets identified by genetic testing, and an impressive range of promising agents to match them to treat cancer in new and more effective ways. In an abstract entitled: “Progress and Prospects of New Drug Research for Colorectal Cancer”, the latest state of the art in colorectal cancer research was assessed by Feng Wang PhD MD, Director of Medical Oncology at Sun Yat-sen University Cancer Center, in Guangzhou, China. Afterwards, she talked with our reporter, Peter Goodwin:

Philippe Moreau MD; IMS 2026: International Myeloma Society President Discusses Key Themes, Future Directions and Challenges in Newly Diagnosed Multiple Myeloma

2026/09/28

GLASGOW, Scotland—Philippe Moreau MD, President of the International Myeloma Society, talks with Audio Journal of Oncology correspondent Sarah Maxwell about the key themes, future directions and challenges in newly diagnosed multiple myeloma under discussion at the 2026 Annual Meeting, including new drugs and the prospects for cure.

Jiujie Cui MD PhD, CSCO 2026: Early Findings Show KRAS-G12D Inhibitor More than Doubles Median Overall Survival in Patients with Advanced Pancreatic Cancer

2026/09/24

JINAN, China—A highly selective drug that inhibits the predominant oncogenic driver (the KRAS-G12D mutation) in advanced pancreatic ductal adenocarcinoma, and minimizes side effects, has shown big promise for keeping patients alive and progression-free. This was in early trial results reported at the 2026 Annual Meeting of the Chinese Society of Clinical Oncology. In phase 1b/2 study results, Chinese researchers reported marked improvements in outcomes that mirror the 2026 findings from the USA reported in the New England Journal of Medicine with a multi-selective RAS inhibitor. Peter Goodwin heard the latest from the study first author: medical oncologist Jiujie Cui MD PhD, from Renji Hospital at Shanghai Jiaotong University School of Medicine, in Shanghai, China.

Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

2026/09/08

CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.

John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

2026/08/31

CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial therapy.Findings were reported at the 2026 Annual Meeting of the American Society of Clinical Oncology.Peter Goodwin got the details from first author John Mascarenhas MD, Professor of Medicine and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Tisch Cancer Institute, Icahn School of Medicine, in Mount Sinai, New York, NY.

David R Spigel MD; ASCO 2026: EGFR Exon-20 Insertion Directed Initial Therapy Cuts Disease Progression in Patients with Advanced Non-Small Cell Lung Cancer

2026/08/25

CHICAGO, USA—For patients with advanced non-small cell lung cancer harboring the rare exon-20 gene insertion,first-line treatment with the targeted drug sunvozertinib monotherapy brought statistically significant anti-tumor efficacy when compared with chemotherapy in the phase three WU-KONG28 study reported to the 2026 Annual Meeting of the American Society of Clinical Oncology by John V Heymach MD PhD, Professor and Chair of Thoracic and Head and Neck Medical Oncology, at the University of Texas MD Anderson Cancer Center, in Houston. After hearing Dr. Heymach’s talk, Audio Journal of Oncology reporter Peter Goodwin caught up with ASCO commentator David R Spigel MD, President and Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee. (An interview with David R Spigel MD, President & Chief Medical Officer, Sarah Cannon Research Institute, Nashville, Tennessee, US)

Robert C. Stein, PhD FRCP; ASCO 2026: Gene Test Finds Most Patients with High Risk ER-positive, HER2-negative Early Breast Cancer Do Not Benefit from Chemotherapy

2026/08/17

The idea that all women with hormone dependent early breast cancers that test negative for the HER2 molecule and have high risk clinical factors should be receive chemotherapy in addition to endocrine therapy is now being strongly questioned. A new study using a gene expression test to predict recurrence risk has shown that most patients do not benefit from adding chemotherapy to their ongoing endocrine treatment. Results from the OPTIMA phase III randomized non-inferiority trial reported at the 2026 annual meeting of the American Society of Clinical Oncology suggest that the current standard of care recommending chemotherapy for high-risk groups needs to be changed. Peter Goodwin got the details of the study findings from first author, Robert C. Stein, PhD FRCP, Professor of Breast Oncology at University College, in London.

Bjørn Henning Grønberg MD PhD; ASCO 2026: Adding Thoracic Radiotherapy Did Not Prolong Lives of Patients with Extensive Stage Small Cell Lung Cancer Being Treated with Chemo-Immunotherapy. COMMENT: David R Spigel MD

2026/07/22

Patients with extensive stage small cell lung cancer did not live longer with thoracic radiotherapy added to their chemo-immunotherapy in a study reported to the American Society of Clinical Oncology 2026 Annual Meeting held in Chicago, USA. First author Bjørn Henning Grønberg MD PhD, Professor and Consultant in Oncology at the Norwegian University of Science and Technology, St. Olavs Hospital in Trondheim, Norway talked with the Audio Journal of Oncology about his group’s findings.

Kevin Kalinsky MD; ASCO 2026: ASCENT-04 Study Finds Sacituzumab Govitecan plus Pembrolizumab Helps Patients with Previously Untreated Metastatic PD-L1 Positive Triple Negative Breast Cancer Live Longer Without Progression Beyond Subsequent Therapies

2026/07/14

CHICAGO, USA—Combining the antibody-drug conjugate sacituzumab govitecan with pembrolizumab immunotherapy for patients with metastatic triple-negative breast cancers testing positive for the programmed death-ligand 1 (PD-L1) led to significant delays of disease progression after subsequent therapy in comparison with standard of care using a combination of chemotherapy with pembrolizumab. That’s according to first author of research reported at the 2026 American Association of Clinical Oncology Annual Meeting Kevin Kalinsky MD, Division Director of Breast Medical Oncology from Emory University at the Winship Cancer Institute, Hematology and Medical Oncology, in Atlanta, USA. He told reporter Peter Goodwin more about the details.

Wing-Lok Chan MBBS; 2026 ASCO: Patients with Advanced Cancer Using The SUPPORT+ Mobile Phone App With Nurse Supervision have Better Quality of Life and Fewer Hospitalizations

2026/07/08

An interview with: Wing-Lok Chan MBBS, Clinical Associate Professor, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China CHICAGO, USA—Patients with advanced cancer had their quality of life preserved and required fewer hospitalizations when they monitored themselves digitally by using the SUPPORT+ mobile phone app prompting better self-management while giving regular access to guidance from a nurse. This was in a randomized controlled study reported to the 2026 Annual Meeting of the American Society of Clinical Oncology by Wing-Lok Chan MBBS, from the Department of Clinical Oncology at the University of Hong Kong, in China. She talked about the findings with Peter Goodwin: